Clinical trials: Lymphoma, B-Cell
Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
The purpose of the study is to evaluate whether treatment with ibrutinib as a monotherapy results in a clinically significant improvement in progression free survival (PFS) as compared to treatment with ofatumumab in patients…
- Trial name
- RESONATE™ (NCT01578707)
- Testing
- ofatumumab, ibrutinib
- Where
- 76 sites in United States, Australia and 8 more
- Volunteers
- 391 people
- Sponsor
- Pharmacyclics LLC.
Diffuse Large B-Cell Lymphoma
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in combination with various agents for the treatment of Relapsed/Refractory (R/R)…
- Trial name
- Javelin DLBCL (NCT02951156)
- Testing
- Avelumab, Utomilumab, Rituximab
- Where
- 29 sites in United States, Australia and 6 more
- Volunteers
- 29 people
- Sponsor
- Pfizer
Diffuse Large B-Cell Lymphoma
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, and…
- Trial name
- LOTIS-8 (NCT04974996)
- Testing
- Loncastuximab tesirine, Prednisone, Rituximab
- Where
- United States
- Sponsor
- ADC Therapeutics S.A.
Lymphoma
BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BAY 59-8862 in treating patients who have refractory…
- Trial name
- NCT00039156
- Testing
- ortataxel
- Where
- 15 sites in United States, Canada
- Sponsor
- Theradex
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia
The purpose of this study is to find answers to the following questions: What is the largest dose of AQ4N that can be given safely one time every three weeks for 24 weeks? What are the side effects of AQ4N when given according to…
- Conditions
- Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
- Trial name
- NCT00109356
- Testing
- AQ4N (Chemotherapy)
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Novacea
Relapsed DLBCL and PT/NKCLs
Clinical Trial of Mitoxantrone HCL Liposome Injection in Patients With Relapsed DLBCL and PT/NKCLs
To study efficacy and safety of Mitoxantrone HCL Liposome Injection in patients with diffuse large B-cell lymphoma and lymphoma peripheral T cell.
- Trial name
- NCT02597387
- Testing
- Mitoxantrone HCL Liposome Injection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Leukemia, Lymphoid, Lymphoma, Non-Hodgkin
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
A study of the safety, side effects, and effectiveness of LOXO-305 in Chinese adults with lymphoma or chronic leukemia who have already had standard of care treatment. Participation could last up to four years.
- Conditions
- Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT04849416
- Testing
- LOXO-305
- Where
- 22 sites in China
- Volunteers
- 87 people
- Sponsor
- Eli Lilly and Company
Relapsed or Refractory Acute Lymphoblastic Leukemia
A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALL
The trial is a single arm, single-center, non-randomized phase I clinical trial which is designed to evaluate the safety and efficacy of C-CAR011 in treatment of adult subjects with relapsed/refractory CD19+ B cells acute…
- Trial name
- NCT03018093
- Testing
- C-CAR-011
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai AbelZeta Ltd.
Lymphoma, B Cell, Lymphoma Non-Hodgkin
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
This study is a Phase 1/2 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV400. The study will enroll patients with relapsed/refractory B-cell malignancies, including large B-cell…
- Conditions
- Lymphoma, B Cell, Lymphoma Non-Hodgkin, High Grade B Cell Lymphoma, Richter Transformation Lymphoma
- Trial name
- NCT07735533
- Testing
- UB-VV400, Rapamycin (sirolimus)
- Where
- United States
- Volunteers
- 274 people
- Sponsor
- Umoja Biopharma
Refractory Diffuse Large B-Cell Lymphoma
A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects
The trial is a single arm, single-center, non-randomized phase I clinical trial which is designed to evaluate the safety and efficacy of C-CAR011 in treatment of refractory DLBCL
- Trial name
- C-CAR011 (NCT02976857)
- Testing
- C-CAR-011
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai AbelZeta Ltd.
Non Hodgkin Lymphoma, Multiple Myeloma
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
This study will provide long-term follow-up for patients who have received treatment with a Juno CAR T-cell product in a Juno-sponsored clinical trial.
- Conditions
- Non Hodgkin Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT03436771
- Testing
- JCAR017, JCARH125
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
Hodgkin's Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL)
A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)
The primary objective of the study is to evaluate the objective response rate (ORR), by cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification criteria 2014 in participants treated with…
- Trial name
- NCT04875195
- Testing
- Pembrolizumab
- Where
- 27 sites in United States, Brazil and 9 more
- Volunteers
- 66 people
- Sponsor
- Merck Sharp & Dohme LLC
Diffuse Large B-cell Lymphoma (DLBCL)
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy.
- Trial name
- OLYMPIA-3 (NCT06091865)
- Testing
- Odronextamab, Rituximab, Cyclophosphamide
- Where
- 195 sites in United States, Australia and 19 more
- Volunteers
- 904 people
- Sponsor
- Regeneron Pharmaceuticals
Non-Hodgkin's Lymphoma
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)
This was a prospective, open-label, Phase III, multicenter, single-arm trial designed to assess the safety, pharmacokinetics, and pharmacodynamics of an alternative dosing rate of rituximab in previously untreated patients with…
- Trial name
- RATE (NCT00719472)
- Testing
- Rituximab, CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone), CVP (cyclophosphamide, vincristine, prednisone)
- Volunteers
- 451 people
- Sponsor
- Genentech, Inc.
Relapsed or Refractory B Cell Non Hodgkin Lymphoma
A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
The purpose of the study is to evaluate the safety、tolerability and preliminary efficacy of B019 in subjects with relapsed or refractory B-cell non-Hodgkin's lymphoma.
- Trial name
- NCT06970496
- Testing
- B019
- Where
- 7 sites in China
- Volunteers
- 48 people
- Sponsor
- Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Diffuse Large B Cell Lymphoma
A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients
The primary objective of the study is to assess the efficiency of SCT400 plus CHOP versus Rituximab plus CHOP in untreated CD20-positive DLBCL Patients.
- Trial name
- NCT02772822
- Testing
- SCT400 plus CHOP, Rituximab plus CHOP
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Sinocelltech Ltd.
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a…
- Trial name
- NCT07221500
- Testing
- NX-5948
- Where
- 43 sites in United States, France and 3 more
- Volunteers
- 100 people
- Sponsor
- Nurix Therapeutics, Inc.
Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR20A in adult subjects with r/r B-cell NHL or r/r…
- Conditions
- Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory, Chronic Lymphocytic Leukemia
- Trial name
- NCT04030195
- Testing
- PBCAR20A, Fludarabine, Cyclophosphamide
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Precision BioSciences, Inc.
Lymphoma, Non-Hodgkin, Lymphoma, Follicular
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT01307267
- Testing
- PF-05082566, rituximab
- Where
- 42 sites in United States, Australia and 3 more
- Volunteers
- 190 people
- Sponsor
- Pfizer
B-Cell Non-Hodgkin Lymphoma (NHL)
Non-Interventional Study of Ranicabtagene Autoleucel Injection for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Establishing real-world data of patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) treated with Ranicabtagene Autoleucel Injection to evaluate its efficacy and safety.
- Trial name
- NCT07888530
- Testing
- Ranicabtagene Autoleucel Injection
- Volunteers
- 200 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.